20 February 2018
e-Health can support healthy ageing and help preventing cardiovascular disease and dementia in elderly people
An innovative e-Health solution, based on an interactive Internet platform, has been developed to support senior citizens in improving their lifestyle to prevent cardiovascular disease, cognitive decline and dementia. Researchers from the HATICE trial presented the solution in a pre-press article published in Journal of Alzheimer's Disease 62(2).
15 February 2018
Poor fitness linked to weaker brain fiber, higher dementia risk
Scientists have more evidence that exercise improves brain health and could be a lifesaving ingredient that prevents Alzheimer’s disease. In particular, a new study from UT Southwestern’s O’Donnell Brain Institute suggests that the lower the fitness level, the faster the deterioration of vital nerve fibers in the brain. This deterioration results in cognitive decline, including memory issues characteristic of dementia patients.
8 February 2018
Alzheimer's disease: dual mechanism of actions of overactive and cytosolic BRCA1 in neuronal death
A new study suggests a dual mechanism of actions of overactive and cytosolic re-localized BRCA1, the major guardian of genomic stability, in neurons death by aberrant DNA damage response and presenilin 1 dysfunction in Alzheimer's disease.
6 February 2018
One in five older adults experience brain network weakening following knee replacement surgery
A new University of Florida study finds that 23 percent of adults age 60 and older who underwent a total knee replacement experienced a decline in activity in at least one region of the brain responsible for specific cognitive functions. Fifteen percent of patients declined across all brain networks the team evaluated.
6 February 2018
Immune system dysfunction may occur early in Alzheimer's disease
An association between inflammation biomarkers in both blood plasma and cerebrospinal fluid and markers of Alzheimer's disease (AD) associated pathology, has been found by researchers at the University of Colorado Anschutz Medical Campus working with the University of Wisconsin Alzheimer's Disease Research Center and the University of California San Francisco Memory and Aging Center. The discovery sheds new light on the pathology of AD as well as on the communication between the brain and the rest of the body.
30 January 2018
Ohio State Study of Brain Pacemaker Shows Promise in Slowing Decline of Alzheimer's
While most treatments for Alzheimer's disease focus on improving memory, researchers at The Ohio State University Wexner Medical Center conducted a study aimed at slowing the decline of problem solving and decision-making skills in these patients. Thin electrical wires were surgically implanted into the frontal lobes of the brains of patients with Alzheimer's disease to determine if using a brain pacemaker could improve cognitive, behavioral, and functional abilities in patients with this form of dementia.
15 January 2018
People with Down Syndrome develop symptoms of Alzheimer's Disease 20-30 years before others
A new multi-centre study, led by researchers from King’s College London and UCL, has found that people with Down Syndrome (DS) develop earlier onset of Alzheimer’s Disease (AD), with an average age of diagnosis between 55 and 56. This is 20 to 30 years earlier than other individuals who are at risk of being diagnosed with AD. It also suggested that individuals with DS may decline faster than other individuals with AD once they are diagnosed.
5 December 2017
Lithium in water associated with slower rate of Alzheimer’s disease deaths
Trace elements of lithium in drinking water can slow death rates from Alzheimer’s disease, Brock University research has found. Rates of diabetes and obesity, which are important risk factors for Alzheimer’s disease, also decrease if there is a particular amount of lithium in the water, says the study, published recently in the Journal of Alzheimer’s Disease.
28 November 2017
Second Phase 3 Study Results for LMTX® published in the Journal of Alzheimer’s Disease
TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer’s disease, published online in the Journal of Alzheimer’s Disease.
28 November 2017
Severity of Post-Operative Delirium Relates to Severity of Cognitive Decline
Researchers from the Harvard affiliated Hebrew SeniorLife Institute for Aging Research (IFAR), in collaboration with scientists from Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School (HMS), and Brown University, have found increasing evidence that the level of delirium in post-surgical patients is associated with the level of later cognitive decline in those same patients. Findings from this study were published today in the Journal of Alzheimer’s Disease.
Pages
